OV-Watch®: Fertility Predictor
State of the Art Fertility Prediction While She Sleeps
- Advanced Biosensor and Microprocessor interprets hormone induced chloride ion fluctuations
- Chloride ion surge is the earliest indicator of the fertile window 12
Timing is Crucial
- Proper identification of the fertility window may shorten the time to conception from 6 months to 1 month for the majority of women.6, 7
- By identifying the optimal fertile window, a diagnosis of infertility may be reduced from 1 year to 6 months.8, 9
Dr. Arthur Haney, M.D., Chairman of the Department of Obstetrics and Gynecology at the University of Chicago states, “Couples trying to conceive using the OV-Watch® will be able to predict their ovulation date four days in advance for the first time. This allows couples to reduce the stress involved, and with intercourse on multiple days, increases their cumulative likelihood of pregnancy.”
The highest probability of conception occurs with intercourse on the days prior to ovulation, rather than the day of ovulation itself.2, 3
Spermatozoa may survive for up to 6 days in the female reproductive tract.4
The human egg may only be capable of fertilization for 16 hours after ovulation, but the optimal time could be much less (2-6 hours).5
Easy to Use:
- Lightweight medical watch device worn for 6 hours while she sleeps.
- Begin wearing on the first, second, or third day of menses.
- OV-Watch® automatically detects and measures chloride ion levels transdermally.
- Sophisticated software program predicts the fertile window based on each woman’s cycle characteristics.
- Easy to read screen identifies: Fertile Day 1, 2, 3, 4 and day of ovulation.
Limitations of Traditional Ovulation Testing:
- Urine testing for the LH surge may miss ovulation in up to one-third of women, and 1 in 10 women may see false positive results.10
- “Even if the LH surge identifies a day with good probability of conception, the brief window of time identified, prospectively limits the opportunity to have multiple acts of intercourse before ovulation”.9
Despite widespread usage, recent evidence indicates that BBT is a highly inaccurate means to detect ovulation. The lowest point of temperature and subsequent rise may occur up to 6 days before ovulation, but can also be seen 4 days after ovulation when there is not a chance of pregnancy.11
G. Wright Bates, Jr., M.D., a Reproductive Endocrinologist states:
“OV-Watch uses state of the art technology to accurately predict fertility, increasing many couple’s chance of pregnancy and shortening the time it takes to conceive. Unlike older methods of ovulation detection which may be hard to interpret, or only give 12 – 24 hours warning, OV-Watch reduces the stress of couples who are trying to expand their family, by identifying a 4 or 5 day fertility window where pregnancy is possible.”
OV-Watch® is the only wristwatch-like device that uses advanced technology to identify a woman’s 6 day fertility window. Experts agree that the 4 full days before ovulation hold the highest probability of conception, in part due to the 5-day lifespan of sperm in the female genital tract. OV-Watch® has been found to provide the user with notice up to four days before ovulation during which the user may have the greatest chance of becoming pregnant. There are no devices available that can guarantee success in achieving pregnancy. OV-Watch® has been designed to assist in family planning (conception). Women with regular monthly cycles lasting between 24 and 35 days are suitable candidates to use the OV-Watch® fertility predictor. Women whose menstrual cycles are anovulatory might get misleading results from this device. OV-Watch® can be programmed for use by women with a cycle from 20 days to 39 days in length. Certain personal circumstances, medical conditions, and medications can adversely affect fertility and the body’s natural ability to ovulate, and may prevent pregnancy. These include menopausal symptoms, breast-feeding, impaired liver or kidney function, polycystic ovarian syndrome, and treatments that affect the menstrual cycle, like birth control pills, or any hormonal contraception. If recently pregnant, stopped breast feeding, or recently stopped using hormonal contraception, women may wish to wait until they have had two normal monthly cycles before using the OV-Watch®. Incorrect setup or incorrect wearing of the device, or missing days of wear, may lead to erroneous or inconclusive results. OV-Watch® is not intended for contraception and should not be used by women who are monitoring their cycles for the purpose of avoiding pregnancy.
Protected by one or more of the following patents and patent applications: US Patent 5,685,319 and other US patents pending, patents pending in Canada (2,240,538), and patents granted in Europe (0871402), Australia (#715,905), Mexico (216897) and New Zealand (#323,351). Patents pending in Brazil (PI 9612157-2), Japan (2003-516380) and other intellectual property rights pending and issued around the world.
1.Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. Effects on probability of conception, survival of the pregnancy and sex of the baby. N England J Med 1995; 33:1517-21. 2.Dunson D, Baird D, Wilcox A, Weinberg C. Day-specific probabilities of clinical pregnancy based on two studies with imperfect measures of ovulation. Human Reprod 1999; 14:1835-9. 3.Dunson D. Weinberg C, Baird D, Kesner J, Wilcox Aj. Assessing human fertility using several markers of ovulation. Stat Med. 2001; 20:965-8. 4.Katz DF, Human cervical mucous: research update. Am J Obstet Gynecol 1991;165:1984-6. 5.Harrison KL, Wilson LM, Breen TM, Pope AK, Cummins JM, Hennessey JF. Fertilization of human oocytes in relation to varying delay before insemination. Fertil Steril. 1988; 50:294-7. 6.Hull M, Glazener C, Kelly N, et al. Population study of causes, treatment, and outcome of infertility. Br Med J Clin Res Ed. 1985; 291-1693-7. 7. Hilgers TW, Daly KD, Prebil AM, Hilgers SK. Cumulative pregnancy rates in patients with apparently normal fertility and fertility-focused intercourse. J Reprod Med 1992;37:864-6. 8.Hilgers TW. The medical applications of natural family planning: A contemporary approach to women’s healthcare. Omaha, Nebraska. Pope Paul VI Institute Press, 1991. 9.Stanford JB, While GL, Hatasaka HH. Timing Intercourse to achieve pregnancy: current evidence. Am J Ob Gynecol 2002;100:1333-41. 10.McGovern PG, Myers ER, Silva Susan, et al. Absence of secretory endometrium after false-positive home urine luteinizing hormone testing. Fertil Steril 2004; 82(5):1273-7. 11.Guermandi E, Vegetti W. Reliability of ovulation tests in infertile women. Obstet Gynecol. 2001;97(1):92-6. 12. Doug Marett, MSC, Chief Scientific Officer, Pheromone Sciences Corporation. Data on file, HealthWatchSystems, Inc.